Outcomes of tuberculosis treatment depending on cyp2c19 genotype

Autor:	P. B. Antonenko, V. I. Kresyun
Rok vydání:	2014
Předmět:	medicine.medical_specialty Tuberculosis business.industry Cyp2c19 genotype Isoniazid General Engineering CYP2C19 medicine.disease Gastroenterology Pulmonary tuberculosis Internal medicine Immunology Genotype medicine In patient business Rifampicin medicine.drug
Zdroj:	Klìnìčna farmacìâ. 18:17-21
ISSN:	2518-1572 1562-725X
DOI:	10.24959/cphj.14.1300
Popis:	As proven earlier, in patients with tuberculosis (TB) the concentration of antituberculosis drugs like isoniazid and rifampicin may differ depending on polymorphism of CYP2C19. The aim of the research was to determine the peculiarities of the pulmonary TB course and its outcome after the in-patient treatment depending on CYP2C19 genotype of the patients. The analysis of medical cards from 83 patients with the primary pulmonary tuberculosis at the end of the in-patient treatment in Odessa regional TB dispensary was conducted in 2012 with consideration of CYP2C19 genotype. At the beginning of the treatment the processes of disintegration were 3 times less in patients with *1/*1 genotype than in patients with *1/*2 genotype (10.3% versus 31.8%; P
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::60454102d77c7e0fefd9e5a822bc1934 https://doi.org/10.24959/cphj.14.1300 Zobrazit plný text záznamu